LabCorp Licenses Sequella Technology for TB Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – Drug firm Sequella today announced the licensing of its B-Smart nucleic acid-based technology to Laboratory Corporation of America Holdings for an undisclosed amount.

Under the terms of the agreement, LabCorp will use the B-Smart system to develop a laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis. LabCorp will also commercially use the assay in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece appearing in Newsday likens familial DNA search to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.

Startup companies are taking on personalized medicine, CNET reports.